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MaBACKGROUND Left ventricular (LV) hypertrophy, a key process in human cardiac disease, results from cellular
(hypertrophy) and extracellular matrix expansion (interstitial ﬁbrosis).
OBJECTIVES This study sought to investigate whether human myocardial interstitial ﬁbrosis in aortic stenosis (AS) is
plastic and can regress.
METHODS Patients with symptomatic, severe AS (n ¼ 181; aortic valve area index 0.4  0.1 cm2/m2) were assessed
pre–aortic valve replacement (AVR) by echocardiography (AS severity, diastology), cardiovascular magnetic resonance
(CMR) (for volumes, function, and focal or diffuse ﬁbrosis), biomarkers (N-terminal pro–B-type natriuretic peptide
and high-sensitivity troponin T), and the 6-min walk test. CMR was used to measure the extracellular volume fraction
(ECV), thereby deriving matrix volume (LV mass  ECV) and cell volume (LV mass  [1  ECV]). Biopsy excluded occult
bystander disease. Assessment was repeated at 1 year post-AVR.
RESULTS At 1 year post-AVR in 116 pacemaker-free survivors (age 70  10 years; 54% male), mean valve gradient had
improved (48  16 mm Hg to 12  6 mm Hg; p < 0.001), and indexed LV mass had regressed by 19% (88  26 g/m2 to
71  19 g/m2; p < 0.001). Focal ﬁbrosis by CMR late gadolinium enhancement did not change, but ECV increased
(28.2  2.9% to 29.9  4.0%; p < 0.001): this was the result of a 16% reduction in matrix volume (25  9 ml/m2 to
21  7 ml/m2; p < 0.001) but a proportionally greater 22% reduction in cell volume (64  18 ml/m2 to 50  13 ml/m2;
p < 0.001). These changes were accompanied by improvement in diastolic function, N-terminal pro–B-type natriuretic
peptide, 6-min walk test results, and New York Heart Association functional class.
CONCLUSIONS Post-AVR, focal ﬁbrosis does not resolve, but diffuse ﬁbrosis and myocardial cellular hypertrophy
regress. Regression is accompanied by structural and functional improvements suggesting that human diffuse ﬁbrosis
is plastic, measurable by CMR and a potential therapeutic target. (Regression of Myocardial Fibrosis After Aortic
Valve Replacement; NCT02174471) (J Am Coll Cardiol 2018;71:860–71) © 2018 The Authors. Published by Elsevier on
behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2017.12.035
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861AB BR E V I A T I O N S
AND ACRONYM S
6MWT = 6-min walk test
AS = aortic stenosis
AVR = aortic valve
replacement
CMR = cardiovascular magnetic
resonance
ECV = extracellular volume
fraction
hsTnT = high-sensitivityA ortic stenosis (AS) is the most common valvedisease and a prototype model for afterload-induced heart failure (1,2). Progressive aortic
valve stenosis affects the left ventricle, which adapts
to reduce wall stress and maintains cardiac output.
Macroscopic adaptations are detected as left ventric-
ular (LV) hypertrophy (LVH), whereas microscopic
changes are characterized by cardiomyocyte hyper-
trophy and extracellular matrix expansion, caused
by both focal replacement ﬁbrosis (scar) and reactive,
interstitial diffuse myocardial ﬁbrosis (3–8).SEE PAGE 872
troponin T
LGE = late gadolinium
enhancement
LV = left ventricular
LVEF = left ventricular
ejection fraction
LVH = left ventricular
hypertrophy
LVM = left ventricular mass
LVMI = left ventricular mass
index
NT-proBNP = N-terminal
pro–B-type natriuretic peptide
NYHA = New York Heart
AssociationFollowing aortic valve replacement (AVR, surgical
or transcatheter), LVH regresses by 20% to 30% by 1
year (9–11). Whether this regression is cellular or
interstitial has until recently been difﬁcult to differ-
entiate because it requires paired biopsies for histo-
logical examination. Cardiac magnetic resonance
(CMR) is established as a tool for quantiﬁcation of
focal ﬁbrosis by late gadolinium enhancement (LGE),
but with T1 mapping CMR can now also measure
diffuse ﬁbrosis by quantifying the extracellular vol-
ume fraction (ECV). CMR with T1 mapping differen-
tiates between cellular (myocytes, ﬁbroblast,
endothelial, red blood cells) and extracellular (extra-
cellular matrix, blood plasma) compartments (Central
Illustration) (12–14), and it offers the opportunity to
track dynamic changes in the cell and matrix com-
partments. In AS, outcome is predicted not only by
the extent of LVH at baseline or its regression post-
AVR (10,15–17), but also by focal ﬁbrosis (using LGE)
(3–5) and diffuse ﬁbrosis (using ECV) (18,19). Histo-
logical studies show that myocardial ﬁbrosis accom-
panies cellular hypertrophy (20), and limited invasive
studies suggest that both may regress after AVR (21).
We aimed to demonstrate that human myocardial
ﬁbrosis is plastic and can regress after AVR and that
this regression can be measured noninvasively.
METHODS
This prospective observational cohort study was
conducted in patients with severe, symptomatic AS
who underwent AVR between January 2012 and
January 2015 in a single tertiary referral cardiac cen-
ter, University College London Hospital NHS Trust,
London, United Kingdom. The study was approved by
the ethical committee of the U.K. National Research
Ethics Service (07/H0715/101) and was registered with
ClinicalTrials.gov (Regression of Myocardial Fibrosis
After Aortic Valve Replacement; NCT02174471). The
study conformed to the principles of the Helsinki
Declaration, and all subjects gave written informedconsent. Patients were recruited before pre-
operative evaluation. Pre-AVR and post-
AVR, the comprehensive assessment
included clinical history, blood pressure, 6-
min walk test (6MWT) (22), blood sampling
(for high-sensitivity troponin T [hsTnT] and
N-terminal pro–B-type natriuretic peptide
[NT-proBNP]), electrocardiography, trans-
thoracic echocardiography, and CMR using
the same equipment. Inclusion criteria were
adult patients with severe AS (2 or more of:
aortic valve area <1 cm2, peak pressure
gradient >64 mm Hg, mean pressure gradient
>40 mm Hg, aortic valve velocity ratio <0.25)
who were undergoing AVR with or without
coronary artery bypass grafting. Exclusion
criteria were pregnancy or breastfeeding,
estimated glomerular ﬁltration rate <30 ml/
min/1.73 m2, CMR-incompatible implanted
devices, inability to complete the protocol,
previous valve surgery, or greater then mod-
erate valve disease other than AS. Overall,
48% of patients undergoing surgical AVR for
severe AS at our institution were recruited
(Figure 1).MULTIMODALITY CARDIAC IMAGING. Echocardiog-
raphy was used to assess diastolic parameters and
valve area or velocities (with CMR for regurgitant
volumes if needed). CMR cine imaging was used to
assess LV structure and systolic function. CMR T1
mapping and ECV were undertaken for myocardial
tissue characterization. All analysis was performed by
operators blinded to clinical parameters.
Echocard iography . Clinical transthoracic echocar-
diography was performed using a GE Vivid E9 system
(GE Healthcare, Waukesha, Wisconsin) with a 4-MHz
transducer, following the guidelines of the American
Society of Echocardiography and the European Soci-
ety of Echocardiography (23).
Card iovascu lar magnet ic resonance . CMR was
performed at 1.5-T (Magnetom Avanto, Siemens
Healthcare, Erlangen, Germany), by using a standard
clinical scan protocol with late gadolinium enhance-
ment (LGE) imaging and T1 mapping (by MOdiﬁed
Look-Locker Inversion recovery [MOLLI]) (24) before
and after a bolus of gadolinium contrast (0.1 mmol/kg
of gadoterate meglumine [gadolinium-DOTA, mar-
keted as Dotarem, Guerbet S.A., Paris, France]). Post-
contrast imaging was performed at 10 min (LGE) and
15 min (T1 mapping).
Imaging ana lys i s . CMR image analysis was per-
formed using CVI42 software (version 5.1.2[303],
CENTRAL ILLUSTRATION Extracellular Volume Fraction Dichotomizes the Myocardium Into
Cell and Matrix Compartments
Treibel, T.A. et al. J Am Coll Cardiol. 2018;71(8):860–71.
(A) The in vivo myocardium consists of cells and the surrounding extracellular matrix. Reactive ﬁbrosis is characterized by expansion of the extracellular matrix,
whereas replacement ﬁbrosis follows cell death by focal scar. (B) Cardiovascular magnetic resonance measures both focal ﬁbrosis (scar) by late gadolinium
enhancement imaging, where the scar appears bright, and diffuse ﬁbrosis by extracellular volume fraction (ECV) imaging. The ECV divides the myocardium into cell and
matrix compartments and allows calculation of cell and matrix volumes. (C) A patient with a left ventricular (LV) volume of 100 ml and an ECV of 25% would have
a cell volume of 75 ml and a matrix volume of 25 ml. Regression of left ventricular mass following aortic valve replacement can be driven by matrix regression alone,
where the ECV reduces; by cellular regression alone, where the ECV increases; or by a proportional regression in cellular and matrix compartments, where the ECV
is unchanged.
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862Circle Cardiovascular Imaging, Calgary, Alberta,
Canada); myocardial mass by this method measures
lower than by some other software platforms (25).
LGE was assessed as a measurement of focal ﬁbrosis,whereas ECV and matrix volume were used as mea-
surements of diffuse myocardial ﬁbrosis (Central
Illustration). LGE was quantiﬁed from a short-axis
LGE stack covering the extent of the left ventricle
FIGURE 1 Study Flow Chart
Screened n = 377
Included post CMR = 171
Not recruited: eGFR <30,
pacemaker, patient declined
Excluded pre OP: 10
2 Amyloid
1 Pseudo severe
2 Severe mitral regurgitation
4 Claustrophobia/unwell
1 Anderson Fabry Disease
Excluded post OP: 20
4 amyloid (biopsy proven)
16 Pacemaker
Surgery n = 164
65% tAVR; 32% mAVR
24% AVR+CABG
7% aortic intervention
Medical Management: 3
Died = 11
Phone follow-up only = 21
(declined to attend)
Recruited n = 181 (48%)
Follow-up CMR n = 116
TAVR n = 4
CMR
AVR
Follow-
up
10
3
31
21
A total of 181 patients with severe, symptomatic aortic stenosis were recruited (48% of
all surgical aortic valve replacements [AVR] at our institution [University College London
Hospital NHS Trust, London, United Kingdom]). Before AVR, 10 patients were excluded
(claustrophobia [n ¼ 4], cardiac amyloid [n ¼ 2], severe mitral regurgitation [n ¼ 2],
pseudosevere aortic stenosis [n ¼ 1], Fabry disease [n ¼ 1]), and 3 patients did not
undergo AVR and were treated medically. Following AVR (164 surgical, 4 transcatheter),
4 further patients were excluded because of cardiac amyloid. By 1 year, there were 11
deaths and 16 patients with pacemakers; 21 patients declined follow-up. A total of 116
patients underwent 1-year follow-up assessment. CABG ¼ coronary artery bypass
grafting; CMR ¼ cardiac magnetic resonance; eGFR ¼ estimated glomerular ﬁltration
rate; mAVR ¼ mechanical aortic valve replacement; pre OP ¼ pre-operative;
TAVR ¼ transcatheter aortic valve replacement; tAVR ¼ tissue bioprosthetic aortic valve
replacement.
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863by using a 3-SD threshold (Online Figure 1), and it was
expressed in grams and as a percentage of the left
ventricle. For T1 mapping, 3 short-axis T1 maps (base,
middle, and apex) were manually contoured at the
endocardial and epicardial border, segmented into an
American Heart Association 16-segment model using
the right ventricular insertion points. Partial
voluming of blood was minimized by setting an
automatic offset of 10% from the endocardial and
epicardial borders. Segments with myocardial infarc-
tion (endocardial LGE) on LGE imaging
were excluded. ECV was calculated as: ECV ¼
(1  hematocrit)  [DR1myocardium] / [DR1bloodpool] (26),
where DR1 is the difference in relaxation rates (1 / T1)
pre-contrast and post-contrast (13). Total LV matrix
and cell volumes were calculated from the product of
LV myocardial volume (LV mass [LVM] divided by the
speciﬁc gravity of myocardium [1.05 g/ml]) and ECV
or (1  ECV), respectively. Further details can be
found in the Online Methods section.
STATISTICAL ANALYSIS. Statistical analyses were
carried out using SPSS software version 22 (IBM,
Armonk, New York). All continuous variables are
expressed as mean  SD or median (interquartile
range [IQR]) for skewed data. Normality was checked
using the Shapiro-Wilk test. Categorical variables are
expressed as percentages. Groups were compared
using the independent-samples Student’s t-test for
normally distributed continuous variables, the Mann-
Whitney U test for non-normally distributed vari-
ables, and the Fisher exact test or a chi-square test for
categorical variables. Changes between pre-AVR and
post AVR visits were compared using paired Student’s
t-tests for continuous variables and using Wilcoxon
signed rank test for ordinal variables (New York Heart
Association [NYHA]). Log transformation was applied
to normalize the distribution of NT-proBNP and
hsTnT. To identify predictors of LVM and matrix
regression, all clinical parameters were proposed for
inclusion in a univariate linear regression model, and
the most signiﬁcant predictors per domain were then
entered into a stepwise multivariable model to iden-
tify signiﬁcant independent predictors. A 2-sided
p value of <0.05 was considered signiﬁcant.
RESULTS
STUDY POPULATION. A total of 181 patients with se-
vere, symptomatic AS (age 69  10 years; 56% male)
were recruited. Three patients did not undergo AVR
and were treated medically. Following AVR, 14 pa-
tients were excluded (cardiac amyloid [n ¼ 6] (27),
claustrophobia [n ¼ 4], severe mitral regurgitation
[n ¼ 2], pseudosevere AS [n ¼ 1], Fabry disease [n ¼ 1]).By 1 year, there were 11 deaths and 16 patients with
pacemakers; 21 patients declined follow-up. A total of
116 patients underwent 1-year follow-up assessment
and were included in the analysis, as shown in the
study ﬂowchart (Figure 1). There was no signiﬁcant
difference in baseline characteristics between patients
who completed the follow-up and thosewhodid not, in
particular with regard to age, sex, AS severity, or sur-
gical risk score (all p > 0.05).
BASELINE FINDINGS. Baseline demographic, clin-
ical, echocardiographic, and CMR characteristics of
the follow-up study cohort (n ¼ 116; age 70  10 years
of age; 54% male) are shown in Tables 1 and 2 (Online
Table 1).
Valve stenos is sever i ty . All patients had severe AS
by echocardiography (aortic valve area index 0.40 
0.13 cm2/m2; mean gradient 48  14 mm Hg; peak
TABLE 1 Baseline Clinical Characteristics (N ¼ 116)
Age, yrs 70  10
Male 63 (54)
Trileaﬂet 83 (72)
Bicuspid* 33 (28)
BSA, m2 1.90  0.22
Comorbidities
Hypertension 87 (75)
SBP, mm Hg 133  17
DBP, mm Hg 76  10
Diabetes 23 (20)
Coronary artery disease 34 (29)
Atrial ﬁbrillation 16 (14)
Risk scores
STS, % 1.3 (1.0–2.1)
EuroSCORE II, % 1.4 (1.0–2.4)
Drug history
ACE inhibitor/ARB 51 (44)
Beta-blocker 43 (37)
Statin 74 (64)
Aspirin 51 (44)
Blood
Creatinine, mmol/l 85  26
eGFR, ml/min/1.73 m2 77  21
Hematocrit, % 40.4  4.5
Histology
Collagen volume fraction, %† 7.7 (4.2–12.7)
Values are mean  SD, n (%), or median (interquartile range). *One patient had
unicuspid aortic stenosis (female). †n ¼ 91.
ACE ¼ angiotensin-converting-enzyme; ARB ¼ angiotensin receptor blocker;
BSA ¼ body surface area; DBP ¼ diastolic blood pressure; eGFR ¼ estimated
glomerular ﬁltration rate; EuroSCORE II ¼ European System for Cardiac Operative
Risk Evaluation II score; IQR ¼ interquartile range; LVH ¼ left ventricular hyper-
trophy; NYHA ¼ New York Heart Association; SBP ¼ systolic blood pressure;
STS ¼ The Society of Thoracic Surgeons risk model score.
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determined as calciﬁc AS (n ¼ 83; 72  8 years of age;
52% male), bicuspid AS (n ¼ 32; 59  6 years of age;
66% male), and unicuspid AS (n ¼ 1; 1 35-year-old
female patient) by a combination of echocardiogra-
phy, CMR, and direct inspection during surgery.
Symptoms and funct iona l capac i ty . All but 7 pa-
tients were symptomatic (94%), with dyspnea (95%),
chest pain (32%), and/or syncope (8%). Median 6MWT
distance was 500 m (IQR: 390 to 600 m).
INTERVENTION. The interval between CMR and AVR
was a median of 33 days (IQR: 6 to 62 days). AVR was
carried out using cardiopulmonary bypass with blood
cardioplegia arrest. The valve received was a tissue
(n ¼ 103; 61%), sutureless (n ¼ 7; 4%), or mechanical
valve (n ¼ 54; 32%), with additional bypass grafting in
30 patients (24%) and intervention on the aorta in
11 (7%; interposition graft, reduction aortoplasty,
replacement of the ascending aorta). Mean bypass andcross-clamp times were 91  26 min and 72  25 min,
respectively. Four patients initially referred for surgi-
cal valve replacement underwent transcatheter AVR
after review by the heart valve team andwere included
in the ﬁnal analysis. Perioperativemyocardial biopsies
(n ¼ 91) were analyzed for collagen volume fraction
(median 7.7%; IQR: 4.2% to 12.7%).
LEFT VENTRICULAR REMODELING AT 1 YEAR AFTER
AVR. At 1 year post-AVR, there was a marked
improvement in aortic valve obstruction (mean
gradient 48 16 mmHg to 12 6mmHg; peak gradient
77 20mmHg to 24 11mmHg; both p<0.001) and LV
afterload (valvuloarterial impedance index 4.3 
1.2 mm Hg/ml/m2 to 3.6  0.9 mm Hg/ml/m2). The
changes from pre-operative to post-operative param-
eters are summarized in Table 2.
There was a 19% reduction in indexed LVM (88 
26 g/m2 to 71  19 g/m2; p < 0.001) (Figure 2A), as well
as a reduction in LV end-diastolic volume index and
LV end-systolic volume index, resulting in a reduc-
tion in the mass-to-volume ratio. LV ejection fraction
(LVEF) increased modestly (71  16% to 74  12%;
p < 0.006). LVM regression occurred regardless of the
baseline level of hypertrophy (i.e., also in patients
with normal geometry), although both absolute and
percentage of LVM index (LVMI) regression were
greatest in those patients with the highest LVMI at
baseline (Online Figure 2). On multivariate regression
analysis, high baseline LVMI, elevated baseline
NT-proBNP level, and lower baseline LVEF were
independently associated with greater LVMI regres-
sion (Table 3) (post-operative change in mean aortic
valve gradient did not reach signiﬁcance [p ¼ 0.06]).
MYOCARDIAL FIBROSIS AT 1 YEAR AFTER AVR. ECV
increased from 28.2  2.9% to 29.9  4.0% (p < 0.001)
(Figure 2B); as a result, derived cell volume reduced
by 22% (14.0  11.6 ml/m2) from 64  18 ml/m2 to 50 
13 ml/m2 (p < 0.001) (Figure 2C), and derived matrix
volume reduced by 16% (4.1  5.8ml/m2) from 25 
9 ml/m2 to 21  7 ml/m2 (p < 0.001) (Figure 2D). Native
myocardial T1 was unchanged (1,039  40 ms vs.
1,035  42 ms; p ¼ 0.3). Focal ﬁbrosis in absolute
terms (LGE in g/m2) did not change at follow-up
(6.4  4.9 g/m2 vs. 6.5  4.4 g/m2; p ¼ 0.9), but
expressed as a percentage of the regressed LVM, focal
ﬁbrosis (LGE as %) increased post-AVR (7.2  5.1% vs.
8.9  4.9%; p ¼ 0.001). There were no differences in
ECV, cell, or matrix volume changes according to
coronary artery disease status, although patients with
coronary artery disease had higher hsTnT levels and
focal ﬁbrosis (Online Tables 2 and 3). Matrix regres-
sion was greatest in those patients with the highest
TABLE 2 Changes After Aortic Valve Replacement (N ¼ 116)
Pre-AVR Post-AVR Change p Value
NYHA functional class
I 15 (13) 70 (60) þ55 (þ47) <0.001
II 59 (51) 41 (35) 18 (15)
III 40 (34) 5 (5) 35 (30)
IV 2 (2) 0 2 (2)
6-min walk test, m 477  177* 571  171 þ90 (0 to þ180) <0.001
NT-proBNP, ng/l 50 (26–173) 38 (23–99) 14 (67 to þ9) <0.001
hsTnT, pmol/l 13 (9–20) 11 (7–17) 1 (4 to þ1) 0.002
Echocardiography
Vmax, m/s 4.4  0.6 2.4  0.5 2.1  0.8 <0.001
Peak gradient, mm Hg 77  20 24  11 53  22 <0.001
Mean gradient, mm Hg 48  14 13  6 35  16 <0.001
EOAI, cm2/m2 0.40  0.13 0.84  0.21 þ0.45  0.25 <0.001
LVOT-to-aortic valve VTI ratio 0.23  0.08 0.51  0.12 þ0.28  0.13 <0.001
Zva, mm Hg/ml/m2 4.3  1.2 3.6  0.9 0.8  1.2 <0.001
E-wave, m/s 0.83  0.29 0.83  0.23 þ0.06 (0.20 to 0.14) 0.20
E/A ratio 0.94  0.49 0.91  0.26 0.06 (0.30 to þ0.17) 0.60
E deceleration time, ms 234  72 242  67 þ12 (69 to þ65) 0.70
Mean E/e0 ratio 13.2  5.8 10.8  4.2 1.1 (5.4 to þ1.9) 0.001
LVRPP, mm Hg  beats/min 15,172  2,924 11,140  2,166 3,805 (1,881 to 6,176) <0.001
CMR parameters
LVEDVI, ml/m2 66  23 62  19 2 (12 to þ8) 0.03
LVESVI, ml/m2 22  21 18  13 7 (35 to þ31) 0.003
LVEF, % 71  16 74  12 þ1 (5 to þ10) 0.006
LVMI, g/m2 88  26 71  19 18 (22 to 11) <0.001
Mass-to-volume ratio 1.42  0.37 1.19  0.27 0.22 (0.40 to 0.05) <0.001
LAAI, cm2/m2 13.2  3.0 12.1  2.2 0.5 (1.2 to þ0.9) 0.09
Tissue characterization
LGE 3SD method, g/m2 6.4  4.9 6.5  4.4 0 (2.3 to þ2.0) 0.90
LGE 3SD method, % 7.2  5.1 8.9  4.9 þ2 (10 to þ12) 0.001
T1 myocardium (native), ms 1,039  40 1,035  42 11 (36 to þ26) 0.30
ECV, % 28.2  2.9 29.9  4.0 þ1.2 (þ3.4 to 0.5) <0.001
Cell volume, indexed, ml/m2 64  18 50  13 14.0 (19.2 to 6.3) <0.001
Matrix volume, indexed, ml/m2 25  9 21  7 3.5 (6.8 to 0.8) <0.001
Values are n (%), median (interquartile range), or mean  SD. Bold p values are statistically signiﬁcant. *n ¼ 85.
3SD ¼ 3 SDs; AVAI ¼ aortic valve area index; AVR ¼ aortic valve replacement; CMR ¼ cardiac magnetic resonance; DT ¼ deceleration time; E ¼ peak early velocity of the
transmitral ﬂow; E/A ratio ¼ ratio of early to late ventricular ﬁlling velocities; E0 ¼ peak early diastolic velocity of the mitral annulus displacement; ECV ¼ extracellular volume
fraction; EOAI ¼ effective oriﬁce area index; hsTnT ¼ high-sensitivity troponin T; LAAI ¼ left atrial area index; LGE ¼ late gadolinium enhancement; LVEDVI ¼ left ventricular
end-diastolic volume index; LVEF ¼ left ventricular ejection fraction; LVESVI ¼ left ventricular end-systolic volume index; LVMI ¼ left ventricular mass index; LVOT ¼ left
ventricular outﬂow tract; LVRPP ¼ left ventricular rate pressure product; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association;
SVI ¼ stroke volume index; Vmax ¼ peak velocity through the aortic valve; VTI ¼ velocity–time integral; Zva ¼ valvuloarterial impedance.
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865matrix volume at baseline (Online Figure 3). On uni-
variate regression analysis, matrix regression was
associated with baseline LV parameters (LV size, hy-
pertrophy, systolic and diastolic function), baseline
biomarkers (hsTnT and NT-proBNP), and post-
operative changes in valve hemodynamics (Online
Table 4). On multivariate analysis, high baseline
LVMI, elevated baseline NT-proBNP level, and high
baseline ECV were independently associated with
greater matrix volume regression (Table 3).
FUNCTIONAL IMPROVEMENT. One year after AVR,
patients were less breathless (NYHA functional classimproved by nearly 1 class; p < 0.001) and could walk
farther (6MWT improvement 90 m; p < 0.001). In
addition, both left atrial pressure, reﬂected by a
reduction in the E/e0 ratio (13  6 cm/s to 11  4 cm/s;
p ¼ 0.003) and NT-proBNP levels were reduced
(50 ng/l [IQR: 26 to 173 ng/l] to 38 ng/l [IQR: 23 to
99 ng/l]; p < 0.001). There were no signiﬁcance dif-
ferences in these parameters in patients undergoing
isolated AVR versus patients undergoing AVR and
coronary artery bypass grafting (Online Tables 2
and 3). On multivariate analysis, shorter baseline
6MWT distance and elevated systolic blood pressure
were independently associated with greatest
FIGURE 2 Cell and Matrix Remodeling 1 Year After AVR
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(A) At 1-year post–aortic valve replacement (AVR), there was a 19% reduction in indexed left ventricular (LV) mass (88  26 g/m2 to 71  19
g/m2; p < 0.001) (B) The extracellular volume fraction (ECV) increased unexpectedly from 28.2  2.9% to 29.9  4.0% (p < 0.001).
(C) Derived indexed cell volume (left ventricular mass index  [1  ECV]) reduced by 22% (64  18 ml/m2 to 50  13 ml/m2; p < 0.001), and
(D) derived indexed matrix volume (left ventricular mass index  ECV) reduced by 16% (25  9 ml/m2 to 21  7 ml/m2; p < 0.001).
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866improvements in NYHA functional class, as well as
greatest improvements in 6MWT distance (Online
Tables 5 and 6). Baseline parameters, AS severity,
and biomarker (hsTnT or NT-proBNP) levels were not
predictive of improvement in 6MWT distance.
DISCUSSION
In this study we sought to understand the dynamic
nature of cellular and matrix components in
myocardial hypertrophy by exploring reverse
myocardial remodeling in AS at 1 year post-AVR. We
show that myocardial cellular hypertrophy and
extracellular matrix expansion (diffuse ﬁbrosis)
regress, and these changes are accompanied by
structural, functional, and biomarker improvement.Furthermore, the study establishes that car-
diomyocyte loss is irreversible, as evidenced by the
persistence of focal replacement ﬁbrosis (LGE) after
AVR. Moreover, these ﬁndings provide validation that
CMR can be used to characterize and monitor the
extent of cellular hypertrophy and myocardial
ﬁbrosis, thereby differentiating between focal ﬁbrosis
(scar) and diffuse ﬁbrosis secondary to accumulation
of ECM and, importantly, conﬁrming myocardial
ﬁbrosis regression noninvasively, similar to that re-
ported >25 years ago requiring invasive myocardial
biopsies (28,29).
The concept of reverse myocardial remodeling af-
ter removal of a pathological insult has been studied
both by echocardiography and by CMR. LVH (i.e.,
combined cell and matrix compartments) is known to
TABLE 3 Predictors of Change in Indexed Left Ventricular Mass and Indexed Matrix Volume After Aortic Valve Replacement
Univariate Predictors Multivariate Predictors*
Beta 95% CI p Value Beta 95% CI p Value
Predictors of change in LVMI
after AVR†
Baseline LVMI, g/m2 0.4 0.4 to 0.3 <0.001 0.13 0.23 to 0.04 0.004
Baseline NT-proBNP, ng/l 0.06 0.08 to 0.03 <0.001 0.01 0.02 to 0.01 0.01
LVEF, % 0.34 0.16 to 0.51 <0.001 0.23 0.01 to 0.45 0.04
D mean AV gradient, mm Hg 0.20 0.06 to 0.34 0.006 0.14 0.01 to 0.28 0.06
Age 0.24 0.01 to 0.47 0.04 NS
Systolic BP, mm Hg 0.40 0.01 to 0.7 0.04 NS
LGE, g 0.7 1.2 to 0.1 0.02 NS
ECV, % 245 442 to 48 0.02 NS
Prosthesis size 3.66 5.92 to 1.4 0.002 NS
Predictors of change in indexed
matrix volume after AVR‡
Baseline LVMI, g/m2 0.12 0.15 to 0.08 <0.001 0.82 0.12 to 0.05 <0.001
Baseline NT-proBNP, ng/l 0.01 0.015 to 0.006 <0.001 0.004 0.008 to 0.001 0.03
ECV, % 0.87 1.19 to 0.56 <0.001 34.8 68.5 to 1.0 0.04
LVEF, % 0.14 0.07 to 0.20 <0.001 NS
D mean AV gradient, mm Hg 0.071 0.002 to 0.139 0.04 NS
Age 0.078 0.034 to 0.191 0.20 NS
Male 2.23 4.40 to 0.62 0.04 NS
LGE, g 0.12 0.22 to 0.01 0.032 NS
E/A ratio 3.99 6.33 to 1.64 0.001 NS
hsTnT, pmol/l 2.90 4.47 to 1.34 <0.001 NS
Prosthesis size 0.55 0.97 to 0.12 0.012 NS
CVF, % 0.13 0.40 NS
Bold p values are statistically signiﬁcant. *Stepwise multivariate linear regression model. †LVMI at baseline minus LVMI at 1 year post-AVR. ‡Indexed matrix volume at baseline
minus indexed matrix volume at 1 year post-AVR.
D ¼ change; AV ¼ aortic valve; BP ¼ blood pressure; CI ¼ conﬁdence interval; CVF ¼ collagen volume fraction; LVMI regression ¼ reduction in LVMI (negative); Matrix volume
regression ¼ reduction in matrix volume (negative). other abbreviations as in Table 2.
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867regress by 20% to 30% by 1 year post-AVR (9–11). We
now show that both cell regression and matrix
regression contribute to the reduction in LVH over
this period (Figure 3).
Combined with our previous data showing that at
6 months post-AVR only cellular hypertrophy re-
gresses (30), this study suggests that the timeline
for cardiomyocyte and extracellular matrix re-
sponses to afterload reduction are different, with
remodeling of the extracellular matrix being slower.
Diffuse ﬁbrosis enhances myocardial tensile
strength and 3-dimensional force delivery but at the
expense of reduced distensibility. Dense collagen
meshwork within the subendocardium seen in AS
can be considered pathological in that it entraps
muscle ﬁbers and causes active stiffness to fall
while impairing distensibility (31). This current work
translates the biopsy ﬁndings from >30 years ago
by Hans-Peter Krayenbuehl and his group (29) into
an era where AS is a different disease and nonin-
vasive imaging by CMR offers in vivo whole heart
myocardial tissue characterization. It is importantto recognize that the demographic features of
patients with severe AS have dramatically changed
over this period of time: First, the small cohort
(n ¼ 20 vs. n ¼ 116) in the earlier study was younger
and predominantly male (mean age 52 years; range
25 to 67 years; 35% women), in contrast to our
cohort, which had a mean age 70 years, with 44%
women. Second, advances in surgical technique
have improved perioperative myocardial preserva-
tion, and advances in prosthesis technology offer
better hemodynamic performance and valve
durability.
Previous data by Villari et al. (21) suggested no
change in interstitial ﬁbrosis at 2 years post-AVR, but
these data were from subendocardial samples rather
than a global, “whole heart” measure as in our cohort.
Location of the biopsy sample is crucial, as we have
shown in previous work (32), where the sub-
endocardial portion of the myocardium was domi-
nated by replacement focal ﬁbrosis decreasing from
superﬁcial to deep such that reactive ﬁbrosis pre-
dominated in the midmyocardium.
FIGURE 3 Reverse Myocardial Remodeling After AVR
A 66-year-old man with severe aortic stenosis (peak velocity 4.66 m/s; mean gradient 57 mm Hg; aortic valve area 0.5 cm2). Cardiac magnetic
resonance before aortic valve replacement (AVR) showed concentric left ventricular (LV) hypertrophy (133 g/m2). Late gadolinium
enhancement (LGE) demonstrated limited nonischemic focal scar (5.3 g/m2 [4%]). Extracellular volume fraction (ECV) was 27.5%. At 1 year
after AVR (mechanical bileaﬂet valve), there was a 22% reduction in LV mass (to 104 g/m2). The LV mass regression resulted from a 24%
reduction in cell volume and a 17% reduction in matrix volume, so the ECV rose to 29.1%. The focal ﬁbrosis (late gadolinium enhancement
[LGE]) was unchanged (5.4 g/m2 [5%]), but it slightly increased when it was expressed as a percentage of the LV mass.
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sion noninvasively by CMR (as a surrogate for diffuse
ﬁbrosis) not only reﬂects a key biological response, but
also has the potential to be used in drug development
to validate proof-of-concept efﬁcacy of drugs targeting
myocardial ﬁbrosis. The possibility of inﬂuencing
myocardial (cellular and interstitial) remodeling with
pharmacological interventions (33–35) requires a bet-
ter understanding of the intricate interplay
throughout all stages of disease. Noninvasive tracking
of cellular and extracellular components maypotentially establish the transition point between
adaptive and maladaptive remodeling and provide a
reliable method to monitor the response to matrix-
modulating therapies (antiﬁbrotic, antiamyloid) in
the search for new individualized heart failure thera-
pies (36).
Native T1 of the myocardium did not change post-
AVR. The most likely explanation is that these
2 parameters capture different compartments: ECV
captures the extracellular components of the
myocardium, (e.g., extracellular matrix and vascular
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869spaces [capillaries]), whereas native T1 is a composite
signal of both the cellular and extracellular
compartments.
Focal ﬁbrosis identiﬁed by LGE is indicative of
cardiomyocyte necrosis with replacement ﬁbrosis
(i.e., ranging from foci of necrosis to larger
myocardial infarcts). Our data suggest that focal
ﬁbrosis, reﬂected by LGE, does not regress; this is
consistent with previous ﬁndings reported post-AVR
implying that AVR failed to reduce the degree of
focal replacement ﬁbrosis (6,37). In contrast, the
reactive diffuse ﬁbrosis did regress. These ﬁndings
highlight the dynamic nature of the extracellular
matrix in AS that contributes to the pathobiology
because changes in collagen turnover occur as a
result of the reaction of cardiac ﬁbroblasts to both
mechanical and local humoral factors (38,39). Matrix
volume and fraction (ECV) quantiﬁcation may add
more predictive information, particularly given that
our data clearly show that this method identiﬁes
measurable reversibility. This is also important from
an outcome perspective because recent data by Chin
et al. (19) showed that both focal ﬁbrosis (LGE) and
diffuse ﬁbrosis (matrix volume) were univariate
predictors of outcome.
Current management strategies for AS mainly
rely on waiting until the onset of symptoms.
However, it is recognized that for some patients this
treatment is too late; furthermore, there is a
discrepancy between symptom development and
markers of long-term outcome post-AVR (e.g., LGE).
This requires conﬁrmation in asymptomatic pa-
tients; however, the recent PRIMID-AS (Prognostic
Importance of Microvascular Dysfunction in Aortic
Stenosis) study showed that LGE and ECV were
not associated with symptom development (trend
for ECV) (40).
Although existing models of AS may be
simplistic, our current understanding is that AS is a
disease of both the valve and the myocardium.
Thus treatment strategies need to assess both the
hemodynamic insult imposed by the valve lesion
and the extent of myocardial structural remodeling,
particularly when seeking to quantify irreversible
changes and predict outcome. Reduced LVEF,
excessive LVH, abnormal response to exercise, and
critical AS (peak velocity >5 m/s) (15,41), as well as
LGE (3–5), are markers for this and have been
shown to predict adverse outcome. Although LVH
regression occurs early post-AVR (42,43), myocar-
dial normalization is not always possible. We show
that focal replacement ﬁbrosis is not plastic butirreversible, which is not surprising, but it may
represent a point in the clinical progression of AS at
which valve replacement should be recommended
to prevent further irreversible damage. If this tran-
sition point to maladaptive remodeling could be
anticipated, then intervention could be performed
before the emergence of irreversible focal replace-
ment scar; a combination of blood and imaging
biomarkers may be able to identify these transition
points in the future. Finally, drug therapies could
be used post-AVR to augment or accelerate
normalization of both cell hypertrophy and diffuse
ﬁbrosis.
STUDY LIMITATIONS. There are limits to an exclu-
sively noninvasive approach. The ECV technique is
measuring extracellular water, which tracks ﬁbrosis,
but there are other explanations: vasodilation,
edema, and amyloid. Compensatory capillary vaso-
dilation (hyperemia) would cause elevated native
myocardial T1 and ECV (44). However, AS is believed
to have a reduced capillary density (45), and the
changes found here are too large for blood volume—
16% of total myocardial volume. We also saw no
predicted change in native T1. Edema could be a
cause, which has been described in increased after-
load (46). However, these patients had normal base-
line myocardial T2. A dual pathological process with
occult amyloid was speciﬁcally sought and excluded
(n ¼ 6), so it was not present (27). ECV quantiﬁcation
excluded infarct LGE but included nonischemic LGE,
as per guideline recommendation (26). Although
exclusion of all areas of LGE may appear theoretically
attractive, it would be practically challenging to limit
the ECV measurement area to exclude pixels of non-
infarct LGE (highlighted by our thresholding
method). Ultimately, the inclusion of areas of non-
infarct LGE in the ECV measurement did not affect
the overall regression trend because the amount of
LGE did not change at follow-up. Although the lack of
change in LGE area post-AVR may contribute to the
ECV increase post-AVR, it will simultaneously lead to
underestimation of the proportion of matrix regres-
sion. Previous studies (47) used cutoffs of ECV to
predict the presence of LGE, but this approach would
not be appropriate. We have shown recently that LGE
and ECV increases probably reﬂect different mecha-
nisms, and that technical aspects are important (32):
whereas ﬁbrosis elevates ECV, physiological cell hy-
pertrophy lowers ECV (as seen in athletic hypertro-
phy [48]). LGE does not capture this cellular
component.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with AS, myocardial hypertrophy and diffuse
ﬁbrosis regress during the ﬁrst year after AVR,
whereas focal ﬁbrosis is relatively irreversible.
TRANSLATIONAL OUTLOOK: Further research
should be conducted to develop matrix-modulating
therapies that prevent the development of irreversible
focal
ﬁbrosis.
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870Other limitations of the present study include that
it is a single-center study and it focused on surgical
AVR by noninvasive CMR assessment without paired
histological examination. Pressures were determined
by noninvasive, echocardiography-derived values
only. Patients in renal failure or with pacemakers are
not represented (this excluded 7% of possible pa-
tients). Some patients declined follow-up, but there
was no signiﬁcant difference in baseline characteris-
tics between patients who completed the follow-up
and those who withdrew.
CONCLUSIONS
In aortic stenosis following AVR, both cellular hy-
pertrophy and diffuse ﬁbrosis regress, and these
changes are accompanied by structural, functional
and biomarker improvement. Both cellular hypertro-
phy and diffuse ﬁbrosis are plastic, whereas focal
replacement ﬁbrosis is irreversible.ADDRESS FOR CORRESPONDENCE: Dr. James C.
Moon, Barts Heart Centre, St. Bartholomew’s Hospi-
tal, 2nd Floor, King George V Block, London EC1A
7BE, United Kingdom. E-mail: james.moon@
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